(-)-Etoposide
(-)-Etoposide Brand names, (-)-Etoposide Analogs
(-)-Etoposide Brand Names Mixture
- No information avaliable
(-)-Etoposide Chemical_Formula
C29H32O13
(-)-Etoposide RX_link
http://www.rxlist.com/cgi/generic2/etopophos.htm
(-)-Etoposide fda sheet
(-)-Etoposide msds (material safety sheet)
(-)-Etoposide Synthesis Reference
No information avaliable
(-)-Etoposide Molecular Weight
588.557 g/mol
(-)-Etoposide Melting Point
236-251 oC
(-)-Etoposide H2O Solubility
58.7 mg/L
(-)-Etoposide State
Solid
(-)-Etoposide LogP
1.197
(-)-Etoposide Dosage Forms
Solution; Capsule; Liquid
(-)-Etoposide Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
(-)-Etoposide Pharmacology
Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.
(-)-Etoposide Absorption
Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50%.
(-)-Etoposide side effects and Toxicity
Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).
(-)-Etoposide Patient Information
Patients are generally advised to call their doctor in case of fever, symptoms of infection or painful injection sites, as these may progress severely without adequate medical attention. It is advised to drink lots of fluids after treatment to prevent damage to the bladder and kidneys, typically 1.5 to 3.5 litres of water on the day of treatment and for several days after.
(-)-Etoposide Organisms Affected
Humans and other mammals
